Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
CEO Brett Monia Took The Helm At Start Of Transition
Executive Summary
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.
You may also be interested in...
Alnylam Drops Label-Expansion Effort For Onpattro After FDA Complete Response
Giving up on adding a cardiomyopathy indication to Onpattro’s label, Alnylam now will focus on adding that disease to Amvuttra’s label. Onpattro got a thumbs-up from an FDA advisory panel in September.
Finance Watch: No Big Post-ASCO Follow-On Frenzy, But Biotech Had A Good Week
Public Company Edition: Follow-on offerings did not surge after ASCO, but Day One and Cogent raised $150m-plus. Also, IQVIA and Ionis sold $1.25bn and $500m in notes, while Krystal and Lexicon grossed $160m and $125m from post-approval offerings.
AstraZeneca/Ionis’s Eplontersen Shows Competitive Efficacy In ATTR Polyneuropathy At 66 Weeks
Patients continued to improve across all three Phase III NEURO-TTRansform co-primary endpoints with 29 more weeks of treatment, setting up eplontersen to challenge Alnylam’s Amvuttra.